GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cyclo Therapeutics
Cyclo Therapeutics is a biotech company focused on treating rare diseases. Its stock price is volatile and dependent on clinical trial results. The chart reflects investor confidence in the potential of its drugs.
Share prices of companies in the market segment - Specialized pharma
Cyclo Therapeutics is a biopharmaceutical company developing cyclodextrin-based drugs for the treatment of rare metabolic and neurological diseases. We have classified it as a "Specialty Pharmaceutical." The chart below shows the dynamics in the orphan disease sector.
Broad Market Index - GURU.Markets
Cyclo Therapeutics is a biopharmaceutical company developing cyclodextrin-based drugs for the treatment of rare metabolic diseases. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Cyclo compares to it.
Change in the price of a company, segment, and market as a whole per day
CYTH - Daily change in the company's share price Cyclo Therapeutics
Cyclo Therapeutics' daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for rare diseases.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare neurodegenerative diseases. Biotech focused on rare diseases is a volatile niche. The chart below shows the average fluctuations in this sector, allowing you to assess the risks and potential of CYTH stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Cyclo Therapeutics is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cyclo Therapeutics
Cyclo Therapeutics' year-end performance is a story about the development of its drug for the treatment of a rare genetic disease. Its market capitalization over the next 12 months depends entirely on clinical trial data. The success of its lead candidate, which can treat Niemann-Pick disease type C, will be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Cyclo, a late-stage biotech company, develops drugs for rare diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cyclo Therapeutics is a focused bet on defeating a rare genetic disease. Its stock price is completely uncorrelated with the market, but is a direct response to clinical trial data. Its earnings chart is a heartbeat of patient and investor hopes, where scientific data is king.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cyclo Therapeutics
Cyclo is a biopharmaceutical company focused on rare diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of its lead drug's trial results is the primary driver.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Cyclo Therapeutics is developing a drug to treat a rare genetic disorder, Niemann-Pick disease type C. This is a highly specialized niche in biotechnology. The dynamics of the orphan disease sector reflect the willingness of investors and regulators to support development for small patient groups. Cyclo's success depends entirely on the results of its research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cyclo Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare neurodegenerative diseases. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its potential to treat Niemann-Pick disease type C has impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cyclo Therapeutics
Cyclo Therapeutics is a late-stage biotech company developing a treatment for the rare genetic disorder Niemann-Pick disease type C. Its weekly stock price is highly sensitive to news about clinical trials and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Cyclo Therapeutics develops drugs to treat rare metabolic diseases. This is a highly specialized pharmaceutical niche with high potential. The chart will show whether the company's stock price performance is driven by its own clinical trials or reflects general trends in the orphan disease sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cyclo Therapeutics is a biotech company whose stock moves on news about clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news.
Market capitalization of the company, segment and market as a whole
CYTH - Market capitalization of the company Cyclo Therapeutics
Cyclo Therapeutics' market capitalization reflects its focus on treating rare metabolic diseases with its lead drug. Its volatile price is driven by news about clinical trials and regulatory decisions. It's a classic biotech story, where valuation is entirely dependent on science and its approval.
CYTH - Share of the company's market capitalization Cyclo Therapeutics within the market segment - Specialized pharma
Cyclo Therapeutics is a highly specialized pharmaceutical company. Its share of the overall biotech market cap is insignificant, reflecting its focus on rare diseases. This metric reflects the market's perception of its lead drug and its potential for treating Niemann-Pick disease type C.
Market capitalization of the market segment - Specialized pharma
The chart below shows the biotech sector's market capitalization. Cyclo Therapeutics specializes in treating rare metabolic diseases caused by impaired cholesterol transport. This market has the potential to offer hope to patients for whom there is no cure. Cyclo's performance, compared to this market, reflects the success of its unique therapeutic platform.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases such as Niemann-Pick disease. Its market capitalization represents hope for patients. The chart below shows the economic weight of companies solving orphan diseases.
Book value capitalization of the company, segment and market as a whole
CYTH - Book value capitalization of the company Cyclo Therapeutics
Cyclo Therapeutics' foundation is its intellectual property, Trappsol® Cyclo™, a drug for the rare genetic disorder Niemann-Pick type C. The chart is the story of a late-stage biotech company whose balance sheet is built on the capital needed to complete trials and secure regulatory approval.
CYTH - Share of the company's book capitalization Cyclo Therapeutics within the market segment - Specialized pharma
Cyclo Therapeutics is developing a drug to treat a rare genetic disease. The chart shows its share of actual R&D and manufacturing assets. This represents its infrastructure for conducting clinical trials and manufacturing the cyclodextrin-based drug.
Market segment balance sheet capitalization - Specialized pharma
Cyclo Therapeutics is developing drugs to treat rare metabolic diseases. Their value is created in the lab. A book value chart will reflect the value of their R&D base, but it won't convey the potential value of their unique cyclodextrin-based platform.
Book value of all companies included in the broad market index - GURU.Markets
Cyclo Therapeutics' resources include laboratories and partner manufacturing facilities for developing a drug to treat a rare genetic disease. The chart shows how the company built its capital to fight Niemann-Pick disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cyclo Therapeutics
Cyclo Therapeutics fights rare diseases, and its value lies in its intellectual property. The chart below clearly illustrates the venture-like nature of biotech. Its market capitalization is a bet on the success of its platform, and it can be tens of times higher than its book value, reflecting potential, but not guaranteed, future success.
Market to book capitalization ratio in a market segment - Specialized pharma
Cyclo Therapeutics develops drugs to treat rare metabolic diseases caused by cholesterol accumulation. Its valuation depends on the success of its clinical programs. The chart clearly shows how its market capitalization, based on expectations and technology potential, compares to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Cyclo Therapeutics develops drugs to treat rare diseases. The company's value is derived from its intellectual property and clinical trial data. This metric illustrates that the market values the likelihood of its developments, not its current assets, which creates a significant premium to its book value.
Debts of the company, segment and market as a whole
CYTH - Company debts Cyclo Therapeutics
Cyclo Therapeutics develops drugs to treat rare diseases associated with cholesterol metabolism disorders. This chart reflects its financial position. Being in the clinical stage, the company relies entirely on external funding (share issuance) to conduct costly clinical trials.
Market segment debts - Specialized pharma
Cyclo Therapeutics is developing a drug to treat the rare genetic disorder Niemann-Pick disease type C. Developing drugs for orphan diseases is a lengthy and expensive process. This chart shows the funding the company requires to advance its therapy through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cyclo Therapeutics
Cyclo Therapeutics is a biopharmaceutical company developing drugs for rare diseases. This chart shows its financial structure. For a company in the clinical trials stage, debt is a significant burden. All financial resources should be directed toward research, not toward paying interest to creditors.
Market segment debt to market segment book capitalization - Specialized pharma
Cyclo Therapeutics develops drugs to treat rare metabolic diseases. This chart shows the debt burden in the specialty pharmaceutical sector. It is an indicator of the company's ability to finance its clinical trials and the commercialization of drugs for patients with orphan diseases.
Debt to book value of all companies in the market
Cyclo Therapeutics is developing drugs to treat rare metabolic diseases. This is a high-risk, high-reward field. This graph of total market debt demonstrates how favorable the financial environment is overall for raising capital for companies with long-term and unpredictable development cycles.
P/E of the company, segment and market as a whole
P/E - Cyclo Therapeutics
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, particularly Niemann-Pick disease type C. This chart reflects investor hopes for a breakthrough in the treatment of orphan diseases. Its dynamics depend entirely on the results of clinical trials and regulatory decisions.
P/E of the market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases. Its lead candidate targets Niemann-Pick disease type C, a severe genetic disorder. This chart shows the average valuation for the specialty pharmaceutical sector, reflecting how investors value companies tackling orphan diseases.
P/E of the market as a whole
Cyclo Therapeutics is a biopharmaceutical company developing drugs to treat rare metabolic diseases. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cyclo Therapeutics
Cyclo Therapeutics develops cyclodextrin-based therapies for the treatment of rare metabolic diseases, particularly Niemann-Pick disease type C. This chart shows analysts' expectations for future revenue, which depend on the success of clinical trials and commercialization of the therapy for patients with limited treatment options.
%20P%2FE%20Cyclo%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cyclo-Therapeutics&v=1772630699291 "Chart of the company's future (projected) P/E Cyclo Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare diseases, particularly Niemann-Pick disease type C. The chart reflects average profitability expectations for the biotech sector. CYTH's position relative to this benchmark reflects investors' bet that their technology will effectively treat this devastating genetic disorder.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772630699319 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, particularly Niemann-Pick disease type C. This orphan disease has a huge unmet medical need. This chart of overall market expectations is a barometer of investor appetite for funding developments for very small patient groups.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772630699394 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cyclo Therapeutics
Cyclo Therapeutics is developing a cyclodextrin-based drug for the treatment of the rare genetic disorder Niemann-Pick type C. Its financial performance reflects significant investments in clinical trials and regulatory approvals. Future profits depend on the successful commercialization of this orphan drug.
Profit of companies in the market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, specifically Niemann-Pick disease type C. This is an orphan drug. This graph shows the overall profitability of this segment, illustrating how successfully the industry as a whole is bringing to market and monetizing therapies for rare genetic diseases.
Overall market profit
Cyclo Therapeutics is developing a drug to treat a rare genetic disorder, Niemann-Pick disease type C. Like many companies working on orphan diseases, its success depends on science and regulatory approval. The overall economic backdrop, reflected in this chart, is primarily important for attracting long-term capital for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cyclo Therapeutics
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, particularly Niemann-Pick disease type C. This graph reflects analyst expectations for the commercial potential of its orphan disease therapy, which is contingent on successful clinical results and regulatory approval.
%20profit%20of%20the%20company%20Cyclo%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cyclo-Therapeutics&v=1772630699586 "Graph of future (projected) profit of the company Cyclo Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, such as Niemann-Pick disease type C. The company's future depends on the success of its clinical programs and regulatory approvals. This chart reflects forecasts for the pharmaceutical sector, helping to assess Cyclo Therapeutics' potential in the field of orphan diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772630699606 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Cyclo Therapeutics is developing drugs to treat rare metabolic diseases. Like most clinical-stage biotech companies, its prospects depend on the success of its research rather than macroeconomic indicators. This total revenue chart is largely irrelevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772630699615 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cyclo Therapeutics
Cyclo Therapeutics develops drugs to treat rare diseases. This chart shows the premium investors are willing to pay for the potential of its lead drug. It's a classic biotech story, where the hefty valuation is based not on current sales but on the hope of creating a life-saving treatment for patients with orphan diseases.
P/S market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases. Future revenue depends on the success of clinical trials. This pharmaceutical sector chart helps assess how investors view the company's scientific platform and the potential of its drugs to treat diseases with no approved therapy.
P/S of the market as a whole
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, particularly Niemann-Pick disease type C. This market revenue valuation chart helps understand how investors value the company's potential to treat orphan diseases with a high unmet need.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cyclo Therapeutics
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, specifically Niemann-Pick disease type C. This chart shows how the market views the future sales of its lead drug candidate. It reflects investor expectations for regulatory approval and commercial success in treating this rare condition.
%20P%2FS%20Cyclo%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cyclo-Therapeutics&v=1772630699790 "The graph of the company's future (projected) P/S Cyclo Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Cyclo Therapeutics is developing a cyclodextrin-based drug for the treatment of Niemann-Pick disease type C, a rare and fatal genetic disorder. The company's valuation reflects investors' hopes that its lead candidate could become the first approved treatment for the disease, creating significant, albeit risky, commercial potential.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772630699809 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Cyclo Therapeutics is developing drugs to treat rare metabolic diseases. The company aims to solve complex medical problems. In the overall revenue growth picture illustrated by the chart, Cyclo represents an innovative biotech company targeting niche markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772630699849 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cyclo Therapeutics
Cyclo Therapeutics develops drugs for the treatment of rare diseases caused by impaired cholesterol metabolism. The company is in the clinical stage, and its lead candidate is designed for the treatment of Niemann-Pick disease type C. The company does not yet have any revenue from commercial products.
Sales of companies in the market segment - Specialized pharma
Cyclo Therapeutics (CYTH) is developing a cyclodextrin-based drug for the treatment of Niemann-Pick disease type C, a rare genetic disorder that causes cholesterol accumulation in cells. This chart shows revenue in the specialty pharmaceuticals sector. Cyclo Therapeutics is working on a therapy for an orphan disease with a significant unmet need.
Overall market sales
Cyclo Therapeutics develops drugs to treat rare metabolic diseases. Its success depends on scientific breakthroughs. However, the overall economic situation, reflected in this chart, influences global healthcare spending. A strong economy allows healthcare systems and insurers to better cover the costs of treating orphan diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cyclo Therapeutics
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare neurodegenerative diseases, specifically Niemann-Pick disease type C. Future revenue is dependent on the success of clinical trials. This chart reflects analyst forecasts, which estimate the likelihood of commercialization of its therapy for this rare and severe disease.
%20sales%20of%20the%20company%20Cyclo%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cyclo-Therapeutics&v=1772630699975 "Schedule of future (projected) sales of the company Cyclo Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare diseases. This graph shows the potential future revenue of their lead candidate for the treatment of Niemann-Pick disease type C. This is an analyst's perspective on the commercial prospects of this orphan disease therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772630700025 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Cyclo Therapeutics is developing a drug to treat a rare genetic disorder, Niemann-Pick disease type C. The company's success depends entirely on the results of its clinical program. This chart shows overall market sentiment, but for Cyclo Therapeutics and its investors, only scientific data and regulatory decisions are important, as they could change the lives of patients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772630700057 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cyclo Therapeutics
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, such as Niemann-Pick disease type C. The company's profitability is entirely dependent on the success of clinical trials and regulatory approval. The chart illustrates the financial trajectory of a biotech company focused on solving highly complex medical problems.
Market segment marginality - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare diseases, particularly Niemann-Pick disease type C. This chart reflects its operating expenses. Like other biotech companies, the path to profitability lies through successful clinical trials and regulatory approval.
Market marginality as a whole
Cyclo Therapeutics is developing drugs to treat rare metabolic diseases. Its success depends on research results and the ability to cover the costs of expensive therapies. This gross profitability chart reflects the status of payers—insurers and government programs. Their financial stability is key to the drug's commercial success.
Employees in the company, segment and market as a whole
Number of employees in the company Cyclo Therapeutics
Cyclo Therapeutics is focused on developing a treatment for the rare genetic disorder Niemann-Pick disease type C. Working on orphan diseases requires highly specialized expertise. This graph shows the small but dedicated team leading this complex project through clinical trials.
Share of the company's employees Cyclo Therapeutics within the market segment - Specialized pharma
Cyclo Therapeutics is a biopharmaceutical company developing drugs to treat rare diseases. Its narrow focus allows it to work with a highly focused team. This graph shows how much human capital the company concentrates on solving a specific medical problem, where depth of expertise is more important than operational scale.
Number of employees in the market segment - Specialized pharma
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases. The employment trends in the specialty pharmaceutical sector, visible in this chart, demonstrate the growing interest in orphan diseases. For Cyclo Therapeutics, this means increased awareness and potentially accelerated regulatory processes for their drugs.
Number of employees in the market as a whole
Cyclo Therapeutics develops drugs to treat rare metabolic diseases. Bringing drugs for orphan diseases to market is a long and expensive process. A stable economic environment, illustrated by the growth in overall employment in this chart, is critical to attracting the investment needed to complete clinical trials and obtain regulatory approval.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cyclo Therapeutics (CYTH)
Cyclo Therapeutics (CYTH) is another biotech company developing drugs to treat rare diseases. This metric reflects the essence of venture biotech: a small team of scientists and managers manages assets (patents) with potentially enormous value. The chart shows the market valuation of this intellectual capital per employee.
%20of%20the%20company%20Cyclo%20Therapeutics%20(CYTH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cyclo-Therapeutics-CYTH&v=1772630700186 "Chart of market capitalization per employee (in thousands of dollars) of the company Cyclo Therapeutics (CYTH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Cyclo Therapeutics is developing a drug to treat a rare genetic disease. In pharmaceuticals focused on orphan diseases, value is determined by the potential of a single key product. This chart illustrates the enormous value the market places on solving a rare medical problem with the help of a small, focused team.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772630700225 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Cyclo Therapeutics develops drugs to treat rare metabolic diseases, particularly Niemann-Pick disease type C. It's a highly specialized biotech company. This chart for the company illustrates how the market value per employee in the orphan disease field can be very high due to the potentially high price and unmet demand for treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772630700255 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cyclo Therapeutics (CYTH)
Cyclo Therapeutics is another biotech R&D company working on treatments for rare diseases. Like its peers in the sector, it is unprofitable. This chart shows expenses, not revenue: the loss (investment) per employee working on clinical trials and drug development.
%20Chart%20Cyclo%20Therapeutics%20(CYTH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cyclo-Therapeutics-CYTH&v=1772630700418 "Company Profit Per Employee (in thousands of dollars) Chart Cyclo Therapeutics (CYTH)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Cyclo Therapeutics is developing drugs to treat rare metabolic diseases caused by cholesterol accumulation. In a biotech focused on orphan diseases, success depends on a small but highly effective team. This metric demonstrates the value each employee generates, which is critical to assessing a company's potential.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772630700467 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases, particularly Niemann-Pick disease type C (NPC). This chart, showing the market average profit per employee, provides important context. It illustrates the high stakes in biotech specializing in orphan diseases, where the potential return on personnel can be enormous.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772630700481 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cyclo Therapeutics (CYTH)
Cyclo Therapeutics develops cyclodextrin-based drugs for the treatment of rare metabolic diseases. While in clinical trials, the company has no commercial revenue yet. Its growth curve shows zero, and its future growth depends entirely on the successful completion of trials and regulatory approval.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cyclo-Therapeutics-CYTH&v=1772630700546 "Sales chart per company employee Cyclo Therapeutics (CYTH)")
Sales per employee in the market segment - Specialized pharma
Cyclo Therapeutics (CYTH) is a biotech company developing cyclodextrin-based drugs for the treatment of rare metabolic diseases (Niemann-Pick disease type C). This chart shows the average revenue per employee in the sector. It helps investors evaluate the company's capital efficiency during clinical development.
Sales per employee for the market as a whole
Cyclo Therapeutics (CYTH) is a biopharmaceutical company developing cyclodextrin-based therapies for the treatment of rare neurodegenerative diseases such as Niemann-Pick disease type C. The company has no commercial revenue. This metric reflects investment in R&D. Investors use it to predict clinical trial success, which will lead to future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Cyclo Therapeutics (CYTH)
Cyclo Therapeutics (CYTH) is a clinical-stage biotech company specializing in the treatment of a rare genetic disorder (Niemann-Pick disease type C). This chart shows "short" interest. High values reflect the risks associated with developing drugs for ultra-rare diseases, regulatory hurdles, and high cash burn. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cyclo-Therapeutics-CYTH&v=1772630700782 "Short Shares Chart for the Company Cyclo Therapeutics (CYTH)")
Shares shorted by market segment - Specialized pharma
Cyclo Therapeutics (CYTH) specializes in developing cyclodextrin-based drugs for the treatment of rare metabolic diseases, such as Niemann-Pick disease. The chart below shows the overall short position for the biotech sector working on rare (orphan) diseases. It demonstrates the market's confidence in their developments.
Shares shorted by the overall market
Cyclo Therapeutics is a biotech focused on treating rare diseases. It has a long R&D cycle. This chart illustrates the overall market pessimism. For an R&D company without revenue, this is a dangerous period. Investors fear running out of cash for research, and raising a new round in a "fear market" will be impossible.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cyclo Therapeutics (CYTH)
Cyclo Therapeutics (CYTH) specializes in treating rare metabolic diseases, specifically Niemann-Pick disease type C, using its drug, Trappsol Cyclo. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) pending FDA data or "oversold" (below 30) amid capital dilution.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cyclo-Therapeutics-CYTH&v=1772630700873 "RSI 14 indicator chart for the company's stock Cyclo Therapeutics (CYTH)")
RSI 14 Market Segment - Specialized pharma
Cyclo Therapeutics is a biotech company developing Trappsol Cyclo for the treatment of the rare genetic disorder Niemann-Pick disease type C (NPC). This chart measures the overall momentum in the rare disease biotech sector and helps assess whether the entire segment is overheated.
RSI 14 for the overall market
For Cyclo Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYTH (Cyclo Therapeutics)
Cyclo Therapeutics is a biopharmaceutical company focused on the treatment of Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials for the company's key drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYTH-Cyclo-Therapeutics&v=1772630701119 "A chart showing analyst consensus forecasts for the expected stock price. CYTH (Cyclo Therapeutics)")
The difference between the consensus estimate and the actual stock price CYTH (Cyclo Therapeutics)
Cyclo Therapeutics is an R&D company focused on treating a rare and fatal disease (Niemann-Pick C) using its Trappsol platform. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the success of this niche but critical R&D project.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYTH-Cyclo-Therapeutics&v=1772630701200 "A chart showing the difference between the consensus forecast and the actual stock price. CYTH (Cyclo Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Cyclo Therapeutics is a biotech company focused on treating rare metabolic diseases (Niemann-Pick disease type C) using its Trappsol Cyclo platform. This chart shows general expectations for the specialty pharmaceutical sector. It reflects whether experts believe in breakthroughs in rare disease treatments.
Analysts' consensus forecast for the overall market share price
Cyclo Therapeutics is a biotech company specializing in the development of cyclodextrin-based drugs for the treatment of rare metabolic diseases, such as Niemann-Pick disease. This chart reflects the overall market "risk appetite." For Cyclo, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cyclo Therapeutics
Cyclo Therapeutics is a biotech R&D company with one bet: Niemann-Pick Type C (NPC), an ultra-rare, fatal childhood disease. Their signature drug (Trappsol Cyclo) is a drug that removes toxic cholesterol from cells. This chart is a pure indicator of their R&D. Its dynamics are all or nothing, depending entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Specialized pharma
Cyclo Therapeutics is a highly specialized pharmaceutical company. They fight rare diseases (Niemann-Pick disease) using their cyclodextrin-based drug delivery platform. This chart compares their composite index to the sector, showing how their specialized approach compares to others.
The AKIM Index for the overall market
Cyclo Therapeutics is a biotech company using cyclodextrins (Trappsol Cyclo) to treat Niemann-Pick disease type C and Alzheimer's disease. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this rare disease company stacks up against broader economic trends.
